文献速递哮喘

重度哮喘患者从美泊利珠单抗/本拉珠单抗转换为每年两次地莫奇单抗的3A期NIMBLE研究

Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE).
PubMed 文献 · Am J Respir Crit Care Med · 2026-01-01

NIMBLE是一项多中心、随机、双盲、双模拟、平行组3A期非劣效性研究,纳入≥12岁、对美泊利珠单抗100mg每4周或本拉珠单抗30mg每8周治疗≥12个月有临床获益的重度哮喘患者,1:1随机转换为地莫奇单抗100mg每26周皮下注射或维持原生物制剂。52周临床显著急性发作年化率在地莫奇单抗组为0.57(95%CI 0.50-0.64,n=848),活性对照为0.49(95%CI 0.43-0.55,n=839),率比1.16(95%CI 0.98-1.38),因95%CI上限超过预设非劣效界值1.28而未达非劣效。两组多数患者无临床显著急性发作,健康相关生活质量、哮喘控制和肺功能稳定,不良事件相当。

要点

  • 转换为地莫奇单抗未达预设非劣效界值,急性发作率比1.16(95%CI 0.98-1.38)。
  • 两组多数患者无临床显著急性发作,症状控制、肺功能及不良事件相似。
  • 对美泊利珠单抗/本拉珠单抗有应答的重度哮喘患者可考虑安全转换为每年两次地莫奇单抗。

核心结论

  • 虽然统计学非劣效未达到,但两组急性发作率均低,症状控制和肺功能维持稳定。
  • 这项首个重度哮喘转换随机对照试验提示,对美泊利珠单抗或本拉珠单抗有应答的重度哮喘患者可安全转换为每年两次地莫奇单抗。

研究设计与样本

  • NIMBLE(NCT04718389)为多中心、随机、双盲、双模拟、平行组、3A期非劣效性研究。
  • 纳入≥12岁、对美泊利珠单抗100mg每4周皮下注射或本拉珠单抗30mg每8周皮下注射治疗≥12个月有临床获益的重度哮喘患者。
  • 按1:1随机分为地莫奇单抗100mg每26周皮下注射组(n=848)或维持原生物制剂组(n=839)。
  • 主要终点为52周内临床显著急性发作年化率,预设非劣效界值为1.28。

主要发现

  • 52周临床显著急性发作年化率:地莫奇单抗组0.57(95%CI 0.50-0.64),活性对照组0.49(95%CI 0.43-0.55)。
  • 率比(95%CI)为1.16(0.98-1.38),95%CI上限超过1.28,非劣效未达到。
  • 两组多数患者未发生临床显著急性发作。
  • 健康相关生活质量、哮喘控制和肺功能结局在整个研究期间保持稳定。
  • 不良事件在两组间相当。

关键数值与推荐

  • 非劣效界值预设为1.28。
  • 主要终点为52周内临床显著急性发作年化率。

临床怎么用

  • 对美泊利珠单抗或本拉珠单抗有应答的重度哮喘患者,可考虑转换为每年两次地莫奇单抗以减少注射频率。
  • 转换后需关注急性发作风险,尽管多数患者无发作且症状控制与肺功能稳定。

局限性

  • 研究未达到预设的非劣效性界值,转换为地莫奇单抗后急性发作率在数值上略高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Depemokimab is the first ultra-long-acting biologic with high IL-5 binding affinity, high potency, and an extended half-life enabling twice-yearly dosing. OBJECTIVES: Investigate the efficacy and safety of switching to depemokimab in participants with severe asthma already managed with and responsive to short-acting biologic therapies targeting IL-5 or its receptor. METHODS: NIMBLE (NCT04718389) was a multicenter, randomized, double-blind, double-dummy, parallel-group, phase 3A noninferiority study. Participants were ≥12 years old with asthma and documented clinical benefit on mepolizumab 100 mg subcutaneously every 4 weeks or benralizumab 30 mg subcutaneously every 8 weeks for ≥12 months. Participants were randomized 1:1 to depemokimab 100 mg subcutaneously every 26 weeks or maintained on their prior biologic (mepolizumab or benralizumab). The primary endpoint was annualized rate of clinically significant exacerbations over 52 weeks, with predefined noninferiority margin set at 1.28. Safety endpoints included adverse events. MEASUREMENTS AND MAIN RESULTS: Annualized rates (95% confidence intervals [CIs]) of clinically significant exacerbations over 52 weeks were 0.57 (0.50 to 0.64) with depemokimab (n = 848) and 0.49 (0.43 to 0.55) with active comparator (n = 839); the rate ratio (95% CI) was 1.16 (0.98 to 1.38). Since the upper bound of the 95% CI exceeded 1.28, noninferiority was not met. Most participants in both treatment arms experienced no clinically significant exacerbations. Health-related quality of life, asthma control, and lung function outcomes were stable throughout the study. Adverse events were comparable between treatment groups. CONCLUSIONS: While statistical noninferiority was not met, exacerbation rates were low and symptom control/lung function were maintained in both groups. This first randomized, controlled switch trial in severe asthma suggests that participants with severe asthma on mepolizumab or benralizumab may safely switch to twice-yearly depemokimab. People with severe asthma may be treated with injectable biologic medicines to reduce inflammation in the bronchial tubes of the lungs. These medicines (aka biologics) can reduce asthma flare-ups (ie, exacerbations) and improve asthma symptoms; they are considered safer than long-term steroid use. Depemokimab is a newly developed biologic that has been shown to reduce severe exacerbations versus placebo in patients with severe asthma (SWIFT-1/-2 studies). Once injected under the skin, depemokimab works for a 6-month period, so injections are only needed twice a year. Currently available biologics for severe asthma, such as mepolizumab and benralizumab, require injections every 4 to 8 weeks. Since people with asthma may prefer fewer injections and find it easier to stay on less frequent treatment, it is of clinical interest to find out whether those who have previously improved with mepolizumab/benralizumab therapy maintain that improvement when their treatment is switched to depemokimab therapy. This study compared outcomes after 1 year in people with severe asthma who either switched to depemokimab or continued with mepolizumab/benralizumab. A statistical threshold was set to determine whether switching to depemokimab was noninferior (ie, not worse) than continuing mepolizumab/benralizumab. While the study did not meet this threshold for noninferiority, switching to depemokimab was linked to only a marginally higher number of exacerbations per year compared with continuing mepolizumab/benralizumab, and most people in all treatment groups did not experience any exacerbations. Additionally, other outcomes, such as asthma symptoms, lung function, and adverse events were similar between all the treatments. These results indicate that most people with severe asthma can safely and effectively switch from a current short-acting biologic to a twice-yearly treatment regimen with depemokimab.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Chupp, Nagase, Skowasch, et al. Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE). Am J Respir Crit Care Med. 2026. PMID: 41738176. doi:10.1093/ajrccm/aamag031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。